TriSalus Life Sciences (TLSI) Receivables - Net (2022 - 2026)

TriSalus Life Sciences has reported Receivables - Net for 5 years, with the latest figure at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 4.36% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 4.36% YoY), and the FY2025 full-year result was $6.6 million, up 28.59% from the prior year.
• Receivables - Net for Q1 2026 stood at $5.2 million, down from $6.6 million in the prior quarter.
• The five-year high for Receivables - Net was $6.6 million in Q4 2025, with the low at $1.6 million in Q4 2022.
• Historically, Receivables - Net has averaged $4.6 million across 5 years, with a median of $5.0 million in 2024.
• Annual changes were most pronounced in 2023 — Receivables - Net surged 131.21% — and 2026, when it decreased 4.36%.
• TriSalus Life Sciences' Receivables - Net stood at $1.6 million in 2022, then surged by 131.21% to $3.6 million in 2023, then surged by 41.67% to $5.1 million in 2024, then rose by 28.59% to $6.6 million in 2025, then retreated by 20.48% to $5.2 million in 2026.
• The last three Receivables - Net figures came in at $5.2 million (Q1 2026), $6.6 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.